目的 :探讨玉屏风散辅助氯雷他定对小儿过敏性鼻炎患者的疗效、免疫功能及CRP水平的影响研究。方法 :将108例小儿过敏性鼻炎患者按照数字表法随机分为两组。对照组54例给予氯雷他定治疗,观察组54例在对照组基础上加用玉屏风散。比较两组患者临床疗效、免疫功能的差异,并分析其CRP及生活质量评分。结果 :观察组临床总有效率、显效率分别为96.3%、70.4%高于对照组81.5%、46.3%;治疗2周后、治疗4周后观察组CD3、CD4和CD8细胞水平升高,也高于同期对照组,呈升高趋势(P<0.05);治疗2周后、治疗4周后观察组CRP水平降低,也低于同期对照组,呈降低趋势(P<0.05);治疗2周后、治疗4周后观察组生活质量评分升高,也高于同期对照组,呈升高趋势(P<0.05)。结论 :玉屏风散辅助氯雷他定治疗小儿过敏性鼻炎患者效果佳,临床有效率高,改善机体免疫功能及生活质量,降低炎性指标,值得临床选择。 Objective: To investigate the curative effect, immune function and CRP level of Yupingfeng Powder-assisted loratadine in children with allergic rhinitis. Methods: 108 cases of children with allergic rhinitis were randomly divided into two groups according to digital table method. 54 cases in the control group were treated with loratadine, 54 cases in the observation group were treated with Yupingfengsan on the basis of the control group. The differences of clinical efficacy and immune function between the two groups were compared and CRP and quality of life scores were analyzed. Results: The total clinical effective rate and effective rate in the observation group were 96.3% and 70.4%, respectively, higher than 81.5% and 46.3% in the control group. After 2 weeks of treatment, the levels of CD3, CD4 and CD8 in the observation group increased after 4 weeks of treatment (P <0.05). After 2 weeks of treatment, the level of CRP in the observation group was lower than that in the control group (P <0.05), and the level of CRP was lower in the observation group after 2 weeks of treatment (P <0.05) After 4 weeks of treatment, the quality of life scores of the observation group were also higher than those of the control group at the same period, showing an increasing trend (P <0.05). Conclusion: Yupingfeng San adjuvant loratadine treatment of children with allergic rhinitis patients with good effect, high clinical efficiency, improve the body’s immune function and quality of life, reduce inflammatory markers, it is worth the clinical choice.